Determinants of subacute response to clopidogrel: relative impact of CYP2C19 genotype and PGE1/adenylate cyclase signalling

• Published in: Thrombosis research Vol. 136; no. 2; pp. 308 - 314
• Main Authors: Hurst, Nicola L., Nooney, Vivek B., Chirkov, Yuliy Y., De Caterina, Raffaele, Horowitz, John D.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Ltd 01.08.2015
• Subjects: adenylate cyclase; Adenylyl Cyclases - metabolism; Adult; Aged; Aged, 80 and over; Alprostadil - metabolism; blood platelets; clopidogrel; cyclic AMP; Cytochrome P-450 CYP2C19 - genetics; Female; Genotype; Hematology, Oncology and Palliative Medicine; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors - pharmacology; purinergic P2Y12 receptor antagonists; Signal Transduction; Ticlopidine - analogs & derivatives; Ticlopidine - pharmacology; clopidogrel; cyclic AMP; blood platelets; purinergic P2Y12 receptor antagonists; adenylate cyclase; purinergic P2Y 12 receptor antagonists; purinergic P2Y receptor antagonists

and Hypotheses: The signal transduction pathway modulated by activation or blockade of platelet P2Y12 receptors is linked to PGE1-stimulated adenylate cyclase effects, but this link’s impact on P2Y12 receptor antagonist response is uncertain. We therefore tested the hypothesis that pre-treatment pla...